Anti-HLA antibodies in double umbilical cord blood transplantation

Claudio G. Brunstein; Harriet Noreen; Todd E. DeFor; David Maurer; Jeffrey S. Miller; John E. Wagner

doi:10.1016/j.bbmt.2011.04.013

Anti-HLA antibodies in double umbilical cord blood transplantation

Claudio G. Brunstein, Harriet Noreen, Todd E. DeFor, David Maurer, Jeffrey S. Miller, John E. Wagner

Research output: Contribution to journal › Article › peer-review

59 Scopus citations

Abstract

Recent registry data suggest that host-versus-graft alloreactions mediated by anti-donor HLA antibodies in recipients of adult allogeneic hematopoietic stem cells or single-unit umbilical cord blood (UCB) contribute to the risk of graft failure. The present study evaluated the impact of anti-HLA antibodies on engraftment and unit predominance in 126 double-UCB (dUCB) recipients. Eighteen dUCB recipients were identified with at least 1 of 2 UCB units recognized by anti-HLA antibodies directed against donor-directed HLA-specific antibodies (DSAs). Overall, 9 of 12 patients who had DSAs against 1 of the 2 UCB units composing the graft and 5 of 6 patients who had DSAs against both units engrafted. The cumulative incidence of engraftment was similar in patients with and without DSAs (83% vs 78%). Thus, our data do not support a negative effect of anti-HLA antibodies on engraftment, at least in the setting of cyclosporine and mycophenolate mofetil and the conditioning regimens used at the University of Minnesota, and argue against routine screening for use in graft selection before dUCB transplantation. Further studies are needed to fully understand the value of anti-HLA antibody testing in dUCB graft selection and its impact on transplantation outcomes.

Original language	English (US)
Pages (from-to)	1704-1708
Number of pages	5
Journal	Biology of Blood and Marrow Transplantation
Volume	17
Issue number	11
DOIs	https://doi.org/10.1016/j.bbmt.2011.04.013
State	Published - Nov 2011

Bibliographical note

Funding Information:
Financial disclosure: This work was supported in part by grants from the National Cancer Institute ( CA65493 , to Claudio G. Brunstein, Jeffrey S. Miller, Todd E. DeFor, and John E. Wagner, and CA77598 , to Todd E. DeFor), a grant from the Children’s Cancer Research Fund (to John E. Wagner and Todd E. DeFor), an American Society of Blood and Marrow Transplantation Robert A. Good New Investigator Award (to Claudio G. Brunstein), and a Leukemia and Lymphoma Society Scholar in Clinical Research Award (to Claudio G. Brunstein). The authors have no conflicts of interest to disclose.

Keywords

Engraftment
Graft rejection
Unit predominance

Access

10.1016/j.bbmt.2011.04.013

OpenUrl availability

Full text

Cite this

@article{0887588a963043709d3f661c0eebe93b,

title = "Anti-HLA antibodies in double umbilical cord blood transplantation",

abstract = "Recent registry data suggest that host-versus-graft alloreactions mediated by anti-donor HLA antibodies in recipients of adult allogeneic hematopoietic stem cells or single-unit umbilical cord blood (UCB) contribute to the risk of graft failure. The present study evaluated the impact of anti-HLA antibodies on engraftment and unit predominance in 126 double-UCB (dUCB) recipients. Eighteen dUCB recipients were identified with at least 1 of 2 UCB units recognized by anti-HLA antibodies directed against donor-directed HLA-specific antibodies (DSAs). Overall, 9 of 12 patients who had DSAs against 1 of the 2 UCB units composing the graft and 5 of 6 patients who had DSAs against both units engrafted. The cumulative incidence of engraftment was similar in patients with and without DSAs (83% vs 78%). Thus, our data do not support a negative effect of anti-HLA antibodies on engraftment, at least in the setting of cyclosporine and mycophenolate mofetil and the conditioning regimens used at the University of Minnesota, and argue against routine screening for use in graft selection before dUCB transplantation. Further studies are needed to fully understand the value of anti-HLA antibody testing in dUCB graft selection and its impact on transplantation outcomes.",

keywords = "Engraftment, Graft rejection, Unit predominance",

author = "Brunstein, {Claudio G.} and Harriet Noreen and DeFor, {Todd E.} and David Maurer and Miller, {Jeffrey S.} and Wagner, {John E.}",

note = "Funding Information: Financial disclosure: This work was supported in part by grants from the National Cancer Institute ( CA65493 , to Claudio G. Brunstein, Jeffrey S. Miller, Todd E. DeFor, and John E. Wagner, and CA77598 , to Todd E. DeFor), a grant from the Children{\textquoteright}s Cancer Research Fund (to John E. Wagner and Todd E. DeFor), an American Society of Blood and Marrow Transplantation Robert A. Good New Investigator Award (to Claudio G. Brunstein), and a Leukemia and Lymphoma Society Scholar in Clinical Research Award (to Claudio G. Brunstein). The authors have no conflicts of interest to disclose. ",

year = "2011",

month = nov,

doi = "10.1016/j.bbmt.2011.04.013",

language = "English (US)",

volume = "17",

pages = "1704--1708",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Anti-HLA antibodies in double umbilical cord blood transplantation

AU - Brunstein, Claudio G.

AU - Noreen, Harriet

AU - DeFor, Todd E.

AU - Maurer, David

AU - Miller, Jeffrey S.

AU - Wagner, John E.

N1 - Funding Information: Financial disclosure: This work was supported in part by grants from the National Cancer Institute ( CA65493 , to Claudio G. Brunstein, Jeffrey S. Miller, Todd E. DeFor, and John E. Wagner, and CA77598 , to Todd E. DeFor), a grant from the Children’s Cancer Research Fund (to John E. Wagner and Todd E. DeFor), an American Society of Blood and Marrow Transplantation Robert A. Good New Investigator Award (to Claudio G. Brunstein), and a Leukemia and Lymphoma Society Scholar in Clinical Research Award (to Claudio G. Brunstein). The authors have no conflicts of interest to disclose.

PY - 2011/11

Y1 - 2011/11

N2 - Recent registry data suggest that host-versus-graft alloreactions mediated by anti-donor HLA antibodies in recipients of adult allogeneic hematopoietic stem cells or single-unit umbilical cord blood (UCB) contribute to the risk of graft failure. The present study evaluated the impact of anti-HLA antibodies on engraftment and unit predominance in 126 double-UCB (dUCB) recipients. Eighteen dUCB recipients were identified with at least 1 of 2 UCB units recognized by anti-HLA antibodies directed against donor-directed HLA-specific antibodies (DSAs). Overall, 9 of 12 patients who had DSAs against 1 of the 2 UCB units composing the graft and 5 of 6 patients who had DSAs against both units engrafted. The cumulative incidence of engraftment was similar in patients with and without DSAs (83% vs 78%). Thus, our data do not support a negative effect of anti-HLA antibodies on engraftment, at least in the setting of cyclosporine and mycophenolate mofetil and the conditioning regimens used at the University of Minnesota, and argue against routine screening for use in graft selection before dUCB transplantation. Further studies are needed to fully understand the value of anti-HLA antibody testing in dUCB graft selection and its impact on transplantation outcomes.

AB - Recent registry data suggest that host-versus-graft alloreactions mediated by anti-donor HLA antibodies in recipients of adult allogeneic hematopoietic stem cells or single-unit umbilical cord blood (UCB) contribute to the risk of graft failure. The present study evaluated the impact of anti-HLA antibodies on engraftment and unit predominance in 126 double-UCB (dUCB) recipients. Eighteen dUCB recipients were identified with at least 1 of 2 UCB units recognized by anti-HLA antibodies directed against donor-directed HLA-specific antibodies (DSAs). Overall, 9 of 12 patients who had DSAs against 1 of the 2 UCB units composing the graft and 5 of 6 patients who had DSAs against both units engrafted. The cumulative incidence of engraftment was similar in patients with and without DSAs (83% vs 78%). Thus, our data do not support a negative effect of anti-HLA antibodies on engraftment, at least in the setting of cyclosporine and mycophenolate mofetil and the conditioning regimens used at the University of Minnesota, and argue against routine screening for use in graft selection before dUCB transplantation. Further studies are needed to fully understand the value of anti-HLA antibody testing in dUCB graft selection and its impact on transplantation outcomes.

KW - Engraftment

KW - Graft rejection

KW - Unit predominance

UR - http://www.scopus.com/inward/record.url?scp=80054853536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054853536&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.04.013

DO - 10.1016/j.bbmt.2011.04.013

M3 - Article

C2 - 21601639

AN - SCOPUS:80054853536

SN - 1083-8791

VL - 17

SP - 1704

EP - 1708

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 11

ER -

Anti-HLA antibodies in double umbilical cord blood transplantation

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this